CCCC

C4 Therapeutics, Inc. (CCCC) - Q2 2026 10-Q Summary

Business Context and Reporting Period

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing targeted protein degradation (TPD) medicines using its proprietary TORPEDO platform. The company focuses on oncology, inflammation, neuroinflammation, and neurodegeneration. This report covers the quarterly period ended June 30, 2026. As of July 31, 2026, the company had 123,025,136 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Q2 2026 revenue increased slightly by $0.2 million compared to Q2 2025, driven primarily by $2.7 million in revenue from a new Roche Degrader-Antibody Conjugate (DAC) agreement signed in April 2026. This was partially offset by decreases in revenue from the MKDG collaboration (due to prioritizing one KRAS project) and the termination of the Merck collaboration in late 2025.
• Expenses: Total operating expenses decreased by $1.9 million in Q2 2026 compared to the prior year period. Research and Development (R&D) expenses declined by $1.7 million, largely due to reduced personnel costs (lower stock-based compensation and headcount reduction). General and Administrative (G&A) expenses decreased by $0.2 million.
• Liquidity: The company raised $33.5 million in net proceeds through its At-The-Market (ATM) equity program during the six months ended June 30, 2026. Additionally, $15.7 million in Pre-Funded Warrants were exercised during the period.
• Collaborations: A significant new collaboration with Roche (DAC Agreement) was initiated in April 2026, involving a $20.0 million upfront payment and potential milestones exceeding $1.0 billion. The Merck collaboration was terminated in November 2025.

Guidance, Outlook, and Risks

• Clinical Pipeline:
  • Cemsidomide (IKZF1/3 degrader): Phase 2 MOMENTUM trial enrollment for relapsed/refractory multiple myeloma is expected to complete in Q1 2027, with data expected in H2 2027. A Phase 1b trial combining cemsidomide with elranatamab (Pfizer collaboration) is ongoing.
  • CFT8919 (EGFR degrader): The company will not advance this candidate into the next phase of clinical development outside of Greater China at this time, though Betta Pharma is conducting a Phase 1 trial in Greater China.
• Liquidity Outlook: Management expects current cash, cash equivalents, and marketable securities ($300.4 million) to be sufficient to fund operations for at least the next twelve months from the date of issuance (August 2026), potentially extending to the end of 2028 based on current assumptions.
• Capital Needs: The company anticipates needing substantial additional funding to complete development and commercialization. Future financing may involve equity offerings, debt, or collaborations, which could result in dilution.
• Risks:
  • Regulatory & Clinical: Risks include failure of clinical trials to demonstrate safety/efficacy, delays in regulatory approval, and the unproven nature of the TPD modality.
  • Financial: The company has never been profitable and expects to incur losses for the foreseeable future. Reliance on collaboration revenue and potential inability to raise capital on favorable terms.
  • Collaboration Dependence: Significant reliance on partners (Roche, Betta Pharma, MKDG) for development and commercialization; termination of these agreements could impact revenue and program progress.
  • Warrant Exercise: Outstanding Class A and Class B warrants (101.2 million shares total) may not be exercised if the stock price does not exceed the exercise price ($2.22), limiting potential future cash inflows.

Investor Verification Checklist

• Verify the timeline and enrollment status of the Phase 2 MOMENTUM trial for cemsidomide, as this is the primary near-term catalyst.
• Confirm the terms and progress of the new Roche DAC Agreement, specifically the $20 million upfront payment recognition and milestone triggers.
• Monitor the company's cash burn rate and the utilization of the ATM program to assess runway beyond the stated 12-month projection.
• Review the status of the 101.2 million outstanding warrants (Class A, Class B, and Pre-Funded) and the likelihood of cash exercise given the current stock price relative to the $2.22 exercise price.
• Assess the strategic rationale for halting CFT8919 development outside of Greater China and the implications for the Betta Pharma partnership.